JOHNSON & JOHNSON'S $1.8 BIL. CORDIS ACQUISITION WOULD CREATE TITAN IN INTERVENTIONAL CARDIOLOGY; FIRMS BECOME FRIENDLY WITH $109-PER-SHARE DEAL
This article was originally published in The Gray Sheet
Executive Summary
The competitive landscape of the interventional cardiology market will be dramatically altered by Johnson & Johnson's $1.8 bil. merger with Cordis, as J&J is catapulted to the leading position in a field already replete with medical device powerhouses.